Amniotic Membrane Market: Locally Available Amniotic Allografts Increasingly Meeting Needs of Patients with Joint Pain – BioSpace

Transparency Market Research (TMR)has published a new report on theamniotic membrane marketfor the forecast period of2019-2027. According to the report, the global amniotic membrane market was valued at ~US$ 980 Mnin2018and is projected to expand at a CAGR of ~10%from2019to2027.

GlobalAmniotic Membrane Market:Overview

Request for Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=42059

Increase in Research on Stem Cell Biology & Regenerative Medicineto Drive Market

Cryopreserved Amniotic Membrane Products to Dominate Market

Request for Analysis of the COVID19 Impact on Amniotic Membrane Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=42059

Ophthalmology to be Promising Application

Hospitals Account for Major Share of Global Market

North America to Dominate Global Amniotic Membrane Market

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=42059

Global Amniotic Membrane Market: Competitive Landscape

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact

Transparency Market ResearchState Tower,90 State Street,Suite 700Albany NY - 12207United StatesUSA - Canada Toll Free: 866-552-3453Email:sales@transparencymarketresearch.comWebsite:https://www.transparencymarketresearch.com

Go here to read the rest:
Amniotic Membrane Market: Locally Available Amniotic Allografts Increasingly Meeting Needs of Patients with Joint Pain - BioSpace

MDimune Signed a Research Collaboration Agreement with Paracelsus Medical University for EV Therapeutics Development – BioSpace

MDimune Inc., a cell-derived vesicle (CDVs)-based therapeutics company with BioDrone platform technology, announced on April 30th, 2020, the signature of a research collaboration agreement with Paracelsus Medical University (PMU, Salzburg, Austria). PMU will bring their experience to further the companys global development goals.

Those in attendance from PMU were Herbert Resch, Professor and Rector; Michael Nake, Chancellor; Eva Rohde, Professor, Vice Rector and Director of GMP laboratory; and Mario Gimona, Associate Professor and Head of Production GMP. Those in attendance from MDimune were Shin Gyu Bae, Chief Executive Officer; Seung Wook Oh, Chief Scientific Officer; Tae Kee Jeong, Chief Financial Officer; and Hui-Chong Lau, Manager of the CMC team.

The agreement states that PMU will develop a process for producing CDV therapeutics at GMP-compliant scale as well as supply them for the pre-clinical study and the initial phase of human clinical study. PMU has also agreed to establish GMP-grade mesenchymal stem cell banks derived from umbilical cords for MDimune, which will then be used to produce CDVs required for various preclinical and clinical development.

EVs, especially exosomes, have emerged as a novel therapeutic with their roles in intercellular communications. However, the fact that they only naturally occur in minuscule quantities and the difficulties involved in large-scale production have prevented a rapid progress in the commercialization of EVs. MDimune developed BioDrone platform technology to overcome these critical limitations in EV therapeutics. MDimune anticipates that the research collaboration with PMU will accelerate the development of CDVs in therapeutics and the initiation of clinical trials in the US, Europe, and Asia, which will lead to more partnerships in the global market.

MDimune also announced the appointment of Dr. Mario Gimona, a leading exosome expert, as Chief Manufacturing Officer. Dr. Gimona has been heading the stem cell and extracellular vesicle (EV) production unit at PMUs GMP laboratory as well as investigating the clinical potential of multipotent mesenchymal stem cell-derived EVs in the field of regenerative medicine. With his expertise in manufacturing of EV therapeutics, he will be able to help advance the clinical applications of BioDrone platform technology.

We are thrilled to announce a joint research endeavor with Paracelsus Medical University. We are confident that this collaboration will expedite the entry into the clinical phase of development for the company, which will allow us to become a global leader in the field of EV therapeutics and ultimately provide a cure for many patients with devastating diseases around the world, said Bae, CEO of MDimune. Dr. Resch, Rector of PMU also emphasized that combining the individual strengths of MDimune and PMU`s GMP unit will enhance therapy development and ultimately change people`s lives.

About MDimune, Inc.

Founded in 2015, MDimune has been dedicated to changing the world by developing innovative therapeutics. The company has developed BioDrone platform technology, which is a novel technology that uses cell-derived vesicles to achieve highly target-specific drug delivery. The BioDrone platform technology is patented in the US, Europe, China, Japan, and Korea. MDimunes current programs are focused on cancer, COPD and other rare diseases. MDimune is actively pursuing business partnerships with biotech, pharmaceuticals, and hospitals for the potential application of the BioDrone technology in various unmet medical needs. In 2019, MDimune opened its U.S. affiliate BioDrone Therapeutics Inc. in Seattle, WA, to facilitate its global business development.

For more information, visit the company's website at http://mdimune.com/

Contact

Media:

Jinah Han, Ph.D., Consultant, BD (to.jinah.han@gmail.com)

Investor:

Seung Wook Oh, Ph.D. Chief Scientific Officer (swoh@mdimune.com; info@biodroneus.com)

MDimune Inc.

#1003 KOLON Digital Tower-III, 49 Achasan-ro, Seongdong-gu

Seoul 04790 Korea

Tel +82. 2. 2655. 2636

http://www.mdimune.com

Biodrone Therapeutics Inc.

4000 Mason Rd. Suite 300

Seattle, WA 98195

http://www.biodroneus.com

Original post:
MDimune Signed a Research Collaboration Agreement with Paracelsus Medical University for EV Therapeutics Development - BioSpace

Covid-19: How scientists are keeping politics out of the global race for a vaccine – FRANCE 24 English

As the world races to combat the coronavirus, one nation is notably absent from multinational efforts: the United States.But scientists say that for now, the international research community is working together to do all it can.

Global actors are joining forces on multiple fronts to bring the coronavirus pandemic under control. On April 24, the World Health Organization (WHO) held a virtual conference to launch an international collaboration to accelerate the development and production of the health technologies necessary to do so. The United States did not participate in the conference, which culminated in a joint call for action.

Next Monday, May 4, the European Commission will respond to that call by hosting a global virtual conference to raise money from countries and business foundations to fund the development of tests, treatments and a vaccine for the coronavirus. It has invited governments, business leaders, public figures, philanthropists, artists and citizens to help with its efforts to raise the 7.5 billionit has set as its initial target. Announced partners include France, Germany, the United Kingdom, Norway and Saudi Arabia. It remains unclear if the US will take part.

Under President Donald Trumps America First doctrine, the US has tended to favour unilateral action and eschew cooperation with international organisations. Case in point: On March 14, Trump announced that he was suspending funding to the WHO, which has spearheaded the global response to the pandemic. With an annual input of about $400 million, the US is the biggest contributor to the organisation; the reduction in funds comes at a vital moment.

What all that will mean in the battle against a virus that as global health experts have repeatedly reminded us knows no borders and requires coordinated actionremains to be seen.

Politics a separate sphere from science

On the scientific front, the impact may be minimal. While global cooperation and the sharing of expertise and information is critical, it also happens largely without government involvement and, as of now, continues unimpeded, said Laurent Humeau, chief scientific officer at Inovio Pharmaceuticals.

Humeaus team has relied on the sequencing of the genome provided by China, genetic material from Australia and has cooperated with researchers in South Korea and the UK. Its a community that is moving very fast and we need everyone elses help to get a vaccine, he said. Its absolutely critical for us to have this network of scientists.

The Inovio team is part of the WHOs R & D Blueprint, which pulls together a coalition of experts and allows for the rapid activation of research and development activities during epidemics.

And despite the public distance between the US and the WHO, key health personnel from the Centers for Disease Control and Prevention (CDC) and the National Institutes of Health continue to be part of the global scientific dialogue. For now, the international research community is working together to do all it can. We keep pushing as fast its not as fast as we can run, but as fast as we can fly, Humeau said.

Unless governments issue restrictions such as those the US imposed on stem-cell research politics tends to exist in a sphere separate from science, said Gregory Poland, director of the Mayo Clinics Vaccine Research Group andwho also edits the international journal Vaccine. Youre not working in a political framework at least in the US youre working in a scientific framework, Poland said.

Researchers end up primarily communicating through journals and meetings and, perhaps most importantly in the current crisis, on "preprint servers", where researchers place articles before they have gone through peer review and been published. That has been the primary way that scientists have been communicating with one another, Poland said.

There may even be a silver lining to a little bit of distance between researchers, said Peter Hotez, dean for the National School of Medicine at the Baylor College of Medicine. The US and Europe sometimes have different approaches to vaccine development and how to support vaccine science, and that may not be so bad because it creates additional opportunities for innovation, he said.

Pushed to the bottom?

Poland hopes that this pandemic, unlike the ones that preceded it, will finally have helped people understand how interrelated their nations are. Weve had multiple examples now, that anything that happens anywhere on this globe is maybe, at most, 36 hours away from Europe or North America, he said. Theres where you need a lot of cooperation, for example, on surveillance, on what is happening where, because literally days are lives.

Finding a vaccine is only a first step, warned David Salisbury, associate fellow in the Global Health Programme at Chatham House. The fact that scientists are talking to each other is admirable, because sharing what we are learning about vaccine development is, of course, hugely important," Salisbury said. But that is the beginning of the story Ultimately, weve got to get from developing a vaccine to manufacturing and buying it country by country, and then were into a political world that has left the scientists behind The critical thing is not when do we get the first dose, its when do we get enough.

Manufacturing and distributing a vaccine will be herculean tasks for a disease that potentially affects everyone on the planet, and thats where a new set of potential problems arises. You could imagine a philosophy of America First that might actually prevent vaccines manufactured in the US from leaving the US until everyone [there] had been vaccinated, Salisbury said. Or what if the EU says we will prioritise European customers first? Geopolitics becomes really important in what becomes available when and for whom.

Salisbury said that countries that cant afford to pay market rate also risk getting pushed to the bottom of this great long list of customers. The international community needs to consider carefully how what are certain to be scarce supplies to begin with get distributed.

How do we share a hugely valuable resource equitably? he asked. I dont know that we have a solution yet.

Read the original post:
Covid-19: How scientists are keeping politics out of the global race for a vaccine - FRANCE 24 English

Bone Marrow Transplantation Market to Register CAGR 3.6% Increase in Revenue by 2028 End – Cole of Duty

In addition to rapid expansion of bone marrow donor registry, increasing commercialization of cellular therapy and tissue engineering, increased survival rate post bone marrow transplant procedures, and easier access to treatment will be some of the most prominent factors driving thebone marrow transplantation market.

According to the latest research by Persistence Market Research, the global bone marrow transplantation market is expected to exceed US$ 12 Bn by the end of 2028. The bone marrow transplantation market is expected to grow at a CAGR of 3.6% through the forecast period 2018-2028.

Report Highlights:

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/4288

Company Profile

North America Will Continue to Lead the Pack in Bone Marrow Transplantation Market

Increasing per-capita healthcare and private insurance expenditure is a major factor that is expected to maintain the high demand for technologically advanced treatment procedures, such as bone marrow transplantation, over the forecast period. Increasing blood cancer cases and geriatric population are among the key factors expected to boost the demand for bone marrow transplantation in North America.

The increasing prevalence of myeloma in the region is leading to an increase in the execution of bone marrow transplantation procedures through the allogeneic method. Companies engaged in stem cell therapies are expanding their product portfolio to offer sound treatment solutions for diseases caused while undergoing the allogeneic transplant method.

The availability of more than 90% unrelated donors and high healthcare expenditure are among the factors driving the overall bone marrow transplantation market in North America at present.

The American Society for Blood and Marrow Transplant reported an increasing prevalence of leukemia and lymphoma in patients aged 65 years and above, and this age group constituted 25-30% of the total number of bone marrow transplantation recipients in 2014.

In 2015, the Senate and House of Representatives of the US reauthorized the Stem Cell Therapeutic and Research Act of 2005, which led to an increase in the US unrelated donors registry to 200,000 donors.

Germany Will Steer Europes Market for Bone Marrow Transplantation

Rise in per capita GDP is expected to improve the healthcare expenditure in countries such as Germany and Spain. Government policymakers are forcing healthcare providers and public payers to disclose the cost charged and reimbursed to maintain price transparency. Healthcare organizations in Germany spend most of their research funding on adult stem cell research.

Furthermore, Germany spends 11.3% of its GDP on healthcare, which is above the global average. This, in turn, has led to the presence of better healthcare facilities and more advanced research findings on various healthcare issues such as bone marrow transplantation.

Among the 680 centers throughout the Europe, 226 (35%) centers are dedicated to autologous bone marrow transplantation in 2014, with most of the transplants intended for non-malignant disorders. These factors are expected to drive the bone marrow transplantation market in Europe.

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/4288

APAC Reflects Lucrative Potential for Penetration of Bone Marrow Transplantation Procedures

Rise in the number of bone marrow transplantation centers and expanding donor registry are among the factors expected to reduce the gap between bone marrow transplantation providers and recipients in the Asia Pacific bone marrow transplantation market.

The availability of modern healthcare amenities, along with the presence of several companies engaged in stem cell therapies in China, Australia, and Japan, is expected to be a key factor driving the overall bone marrow transplantation market in Asia Pacific.

After the introduction of alleviating procedures for Peripheral Blood Stem Cell (PBSC) transplant, there has been an increase in the number of allogeneic HSCT procedures using PBSC (64% of the total HSCT) in Australia & New Zealand, which is another factor contributing to the growth of the bone marrow transplantation market in the region.

A survey by the Eastern Mediterranean Blood and Marrow Transplant (EMBMT) Group suggests that non-malignant indications accounted for a 36.5% share of the total bone marrow transplantation activities carried out in the MEA region. Countries such as Dubai and Qatar are undertaking initiatives to develop national bone marrow registries to enhance bone marrow transplantation rates.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/4288

The report offers a comprehensive taxonomy of the bone marrow transplantation market based on the transplantation type, indication, end user, and region.

Continued here:
Bone Marrow Transplantation Market to Register CAGR 3.6% Increase in Revenue by 2028 End - Cole of Duty

(COVID-19 UPDATE)Mesenchymal Stem Cells MARKET TO WITNESS INCREASED REVENUE GROWTH OWING TO HEIGHTENED PRODUCT INNOVATIONS IN THE COVID-19 PANDEMIC -…

Mesenchymal Stem Cells Market Latest Research PDF Of COVID 19 Impact Study By eSherpa Market Reports | Top players Genlantis, Inc., Stem cell technologies Inc., Cytori Therapeutics Inc., BrainStorm Cell Therapeutics., Cyagen Biosciences Inc., Aastrom Biosciences, Axol Bioscience Ltd., Advanced Cell Technology Incorporated, EMD Millipore Corporation, Stemedica Cell Technologies, Inc., R&D Systems, Inc., ScienCell Research Laboratories., Cell Applications, Inc., Celprogen, Inc.

Mesenchymal Stem Cells Market Report is exclusive and talks in detail about the current market situations. Also, about the overall market journey in the previous five years along with the prophecy made by the experts in the industry. However, the report also provides the necessary SWOT analysis as its one of the main elements.

In revenue terms, in the worldwide market, the Mesenchymal Stem Cells Market is forecasted to generate the XX% CAGR. the market share, sales, and revenues are shared in this report for the XX industry, from the worldwide market. According to the forecast the worldwide market for the Mesenchymal Stem Cells industry will reach from $XX billion in 2020 to $XX billion in 2027. The market will show the XX% profit in the Mesenchymal Stem Cells industry in the next 7 years.

Get Free Sample PDF Copy (including COVID19 Impact Analysis, full TOC, Tables, and Figures) of Mesenchymal Stem Cells Market Report @ https://www.esherpamarketreports.com/request-sample/es-412584/

Key Businesses Segmentation of Mesenchymal Stem Cells Market:

Global Mesenchymal Stem Cells Market Segment by Type, covers

Global Mesenchymal Stem Cells Market Segment by Applications, can be divided into

The Mesenchymal Stem Cells Market Report Can Answer The Following Questions:

Enquire before purchasing this report @ https://www.esherpamarketreports.com/pre-order-enquiry/es-412584

Table of Contents

1 Mesenchymal Stem Cells Market Overview1.1 Product Overview and Scope of Mesenchymal Stem Cells1.2 Mesenchymal Stem Cells Segment by Type1.2.1 Global Mesenchymal Stem Cells Production and CAGR (%) Comparison by Type (2015-2027)1.3 Global Mesenchymal Stem Cells Segment by Application1.3.1 Mesenchymal Stem Cells Consumption (Sales) Comparison by Application (2015-2027)1.4 Global Mesenchymal Stem Cells Market by Region (2015-2027)1.4.1 Global Mesenchymal Stem Cells Market Size (Value) and CAGR (%) Comparison by Region (2015-2027)1.4.2 United States Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.3 Europe Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.3.1 Germany Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.3.2 UK Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.3.3 France Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.3.4 Italy Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.3.5 Spain Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.3.6 Russia Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.3.7 Poland Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.4 China Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.5 Japan Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.6 India Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.7 Southeast Asia Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.7.1 Malaysia Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.7.2 Singapore Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.7.3 Philippines Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.7.4 Indonesia Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.7.5 Thailand Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.7.6 Vietnam Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.8 Central and South America Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.8.1 Brazil Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.8.2 Mexico Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.8.3 Colombia Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.9 Middle East and Africa Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.9.1 Saudi Arabia Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.9.2 United Arab Emirates Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.9.3 Turkey Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.9.4 Egypt Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.9.5 South Africa Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.9.6 Nigeria Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.5 Global Market Size (Value) of Mesenchymal Stem Cells (2015-2027)1.5.1 Global Mesenchymal Stem Cells Revenue Status and Outlook (2015-2027)1.5.2 Global Mesenchymal Stem Cells Production Status and Outlook (2015-2027)2 Global Mesenchymal Stem Cells Market Landscape by Player2.1 Global Mesenchymal Stem Cells Production and Share by Player (2015-2020)2.2 Global Mesenchymal Stem Cells Revenue and Market Share by Player (2015-2020)2.3 Global Mesenchymal Stem Cells Average Price by Player (2015-2020)2.4 Mesenchymal Stem Cells Manufacturing Base Distribution, Sales Area and Product Type by Player2.5 Mesenchymal Stem Cells Market Competitive Situation and Trends2.5.1 Mesenchymal Stem Cells Market Concentration Rate2.5.2 Mesenchymal Stem Cells Market Share of Top 3 and Top 6 Players2.5.3 Mergers & Acquisitions, Expansion3 Players Profiles4 Global Mesenchymal Stem Cells Production, Revenue (Value), Price Trend by Type

. And More

Click Here For Detailed Table Of Contents

Reasons To Buy:

Purchase this Report with Full Access @ https://www.esherpamarketreports.com/purchase/es-412584/

Contact Us:

Name: Jason George

Email: sales@esherpamarketreports.com

Call :USA: +1 408 757 0510

Organization: eSherpa Market Reports

About Us:

eSherpa Market Reports is the credible source for gaining the market research reports that will exponentially accelerate your business. We are among the leading report resellers in the business world committed towards optimizing your business. The reports we provide are based on a research that covers a magnitude of factors such as technological evolution, economic shifts and a detailed study of market segment.

Read the original here:
(COVID-19 UPDATE)Mesenchymal Stem Cells MARKET TO WITNESS INCREASED REVENUE GROWTH OWING TO HEIGHTENED PRODUCT INNOVATIONS IN THE COVID-19 PANDEMIC -...

Placental Stem Cells (PSCS) Market is Prospering With Healthy CAGR in 2020. Leading Players are Cryo-Cell International, Inc., ESPERITE NV, LifeCell…

This Placental Stem Cells (PSCS) industry report provides comprehensive analysis as follows Market segments and sub-segments, Market size, Market trends and flow, Major Manufacturers Production and Sales Market Comparison Analysis, Drivers and Opportunities, Competitive scene, Product Specification and Major Types Analysis, Supply and demand, Regional Production Market Analysis, Regional Market Performance and Market Share. The Placental Stem Cells (PSCS) market research report covers effectiveness and summary of the marketing research. These results can be employed to make improvements in the business. The report helps to save a large amount of time and money that may get spend on marketing.

Get ExclusiveSample Copy of This Report Herehttps://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-placental-stem-cells-pscs-market

Placentalstem cells(PSCS) market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to growing at a CAGR of 10.25% in the above-mentioned forecast period. Increasing awareness regarding the benefits associates with the preservation of placental derived stem cells will boost the growth of the market.

The major players covered in theplacental stem cells (PSCS) marketreport areCBR Systems, Inc, Cordlife India, Cryo-Cell International, Inc., ESPERITE N.V., LifeCell International Pvt. Ltd., StemCyte India Therapeutics Pvt. Ltd, PerkinElmer Inc, Global Cord Blood Corporation., Smart Cells International Ltd., Vita 34, among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately.DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Market Analysis and Insights of Global Placental Stem Cells (PSCS) Market

Adoption of advances and novel technologies that will lead to the storage and preservation of stem cells, technological advancement in the field of biotechnology, introduction of hematopoietic stem cell transplantation system and growing number of diseases which will helps in accelerating the growth of the placental stem cells (PSCS) market in the forecast period of 2020-2027. Surging number of applications from emerging economies along with rising awareness among the people will further boost many opportunities that will led to the growth of the placental stem cells (PSCS) market in the above mentioned forecast period.

Increasing operation costs along with stringent regulatory framework will likely to hamper the growth of the placental stem cells (PSCS) market in the above mentioned forecast period. Social and ethical issues will be the biggest challenge in the growth of the market.

Thisplacental stem cells(PSCS) market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on placental stem cells (PSCS) market contactData Bridge Market Researchfor anAnalyst Brief, our team will help you take an informed market decision to achieve market growth.

Read Complete Details with TOC Herehttps://www.databridgemarketresearch.com/toc/?dbmr=global-placental-stem-cells-pscs-market

Global Placental Stem Cells (PSCS) Market Scope and Market Size

Placental stemcells(PSCS) market is segmented on the basis of service type and application. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Placental Stem Cells (PSCS) Market Country Level Analysis

Placental stemcells(PSCS) market is analysed and market size insights and trends are provided by country, service type and application as referenced above.

The countries covered in the placental stem cells (PSCS) market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the bone marrow-derived stem cells (BMSCS) market due to the increasing stem cell procedure along with preferences of private stem cell banking over public and surging network of stem cell banking services.

The country section of the placental stem cells (PSCS) market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure growth Installed base and New Technology Penetration

Placental stem cells (PSCS) market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipments, installed base of different kind of products for placental stem cells (PSCS) market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the placental stem cells (PSCS) market. The data is available for historic period 2010 to 2018.

Competitive Landscape and Placental Stem Cells (PSCS) Market Share Analysis

Placental stem cells (PSCS) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies focus related to placental stem cells (PSCS) market.

To Get This Report at an Attractive Cost, Click Herehttps://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-placental-stem-cells-pscs-market

About Data Bridge Market Research:

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475Mail:Corporatesales@databridgemarketresearch.com

Read more from the original source:
Placental Stem Cells (PSCS) Market is Prospering With Healthy CAGR in 2020. Leading Players are Cryo-Cell International, Inc., ESPERITE NV, LifeCell...

Asia-Pacific Animal Stem Cell Therapy Market by Trends, Key Players, Driver, Segmentation, Forecast to 2025 – Latest Herald

Hongchun Research latest addition on Asia-Pacific Animal Stem Cell Therapy market is a research that features comprehensive outlook pertaining to market valuations, market share, profit estimations, and the geographical spectrum of this business. The report precisely describes key obstacles and opportunities for growth, while drawing out competitive standing of market majors, including their portfolio and growth strategies.

Get PDF Sample Copy on Global Animal Stem Cell Therapy Market @https://hongchunresearch.com/request-a-sample/1025

According to the Global Animal Stem Cell Therapy Market Report, the Animal Stem Cell Therapy Market is expected to witness steady to high growth rate owing to the increased demands from various industries, as well as the regions which are developing at a quick pace. The buying capability and rise in disposable incomes is also a major factor here affecting the Global Animal Stem Cell Therapy Market positively. The Global Animal Stem Cell Therapy Market Report covers the rest of the current trends / opportunities / challenges in substantial detail.

Market Segmentation is one of the key factors of any Market Report. The Global Animal Stem Cell Therapy Market report ensures that the customers receive detailed information of all the Animal Stem Cell Therapy market segments and sub-segments, and hence are covered in a much elucidated fashion. The Global Animal Stem Cell Therapy Market is segmented into various types such as by product, application, end users, and regions.

The global Intelligent Intravenous Infusion Pumps market report is a comprehensive study that encompasses top manufacturers, prospective market share, revenue, purchaser volume with respect to dealing volume and global segmentation for the Intelligent Intravenous Infusion Pumps industry. The report further includes market classification and definitions, product and industry overview, manufacturing specifications and cost structure, included raw materials and so on.

In addition to the vast definitive data, the report also sheds light on the past behavior of the market and an upcoming growth graph that is expected to venture in an upwards trajectory despite market fluctuations and trends.

Access Research Report on Global Animal Stem Cell Therapy Market @ https://hongchunresearch.com/report/asia-pacific-animal-stem-cell-therapy-market-1025

Market Segmentation:The Intelligent Intravenous Infusion Pumps report follows an accumulated research methodology that is based on years of experience combined with structured data points acquired from proprietary sources. These methods function with thorough research and analysis split between primary and secondary research combined with an in-house data wrangling process. In general, the data points are gathered from a variety of sources such as vendor projections, product list, research papers and a detailed list of manufacturers. The analysis is than derived into quantitative market values such as qualitative and quantitative qualities, market forecast models, market segmentations and business models that revolve around the Intelligent Intravenous Infusion Pumps industry.

Moreover, the Intelligent Intravenous Infusion Pumps market report clarifies the market segmentation based on various parameters and attributes that can be classified on geographical region, product types and market applications.

The reports shows the different typesvolume and Value in different applications. The major Intelligent Intravenous Infusion Pumps Market (The Northeast, The Midwest, The Southwest, The Southeast, The West) is analyzed, data including: market size, import and export, sale segment market by product type and applications.

Market Analysis by PlayersBDAbbott LaboratoriesSmiths MedicalB. BraunHospiraBaxterMoogCareFusionMindrayZollIradimedTeleflexMedlineZyno MedicalMaxim

Market Analysis by Regions:The NortheastThe MidwestThe SouthwestThe SoutheastThe West

Market Analysis by Types:Constant Volume Control TypeSyringe Injection TypeOthers

Market Analysis by Applications:HospitalClinicOthers

The report also focuses on developing market trends, preferred market channels and market drivers & restraints to name a few.

Get More Information on Global Animal Stem Cell Therapy Industry @ https://hongchunresearch.com/enquiry-before-buying/1025

About HongChun Research:HongChun Research main aim is to assist our clients in order to give a detailed perspective on the current market trends and build long-lasting connections with our clientele. Our studies are designed to provide solid quantitative facts combined with strategic industrial insights that are acquired from proprietary sources and an in-house model.

Contact Details:Jennifer GrayManager Global Sales+ 852 8170 0792[emailprotected]

Original post:
Asia-Pacific Animal Stem Cell Therapy Market by Trends, Key Players, Driver, Segmentation, Forecast to 2025 - Latest Herald

Covid-19 impact on Life Science Reagent Market Analysis and Forecast 2020|Abcam,Emd Millipore,Biolog,Cell Sciences – Cole of Duty

The global Corona impact on Life Science Reagent Market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Life Science Reagent Market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and opportunities of the global Life Science Reagent Market. With qualitative and quantitative analysis, we help you with thorough and comprehensive research on the global Life Science Reagent Market. We have also focused on SWOT, PESTLE, and Porters Five Forces analyses of the global Life Science Reagent Market.

Leading players of the global Life Science Reagent Market are analyzed taking into account their market share, recent developments, new product launches, partnerships, mergers or acquisitions, and markets served. We also provide an exhaustive analysis of their product portfolios to explore the products and applications they concentrate on when operating in the global Life Science Reagent Market. Furthermore, the report offers two separate market forecasts one for the production side and another for the consumption side of the global Life Science Reagent Market. It also provides useful recommendations for new as well as established players of the global Life Science Reagent Market.

Request for Sample Copy of This Report @https://www.reporthive.com/request_sample/2292975

Major Players:

High Throughput Genomics Inc.Illumina Inc.Abbott LaboratoriesAbcamEmd MilliporeBiologCell SciencesLonza Group AgCell Signaling TechnologyThermo Fisher Scientific Inc.Trilink BiotechnologiesCepheid Inc.Olympus Corp.Biomyx TechnologyAbgent Inc.

Segmentation by Product:

Cell Biology ReagentsAnimal ModelsRecombinant ProteinsOthes

Segmentation by Application:

Stem Cell ResearchDNA ResearchRNA ResearchProtein DetectionOthers

For Customised Template PDF Report:https://www.reporthive.com/request_customization/2292975

Competitive Analysis:

Global Life Science Reagent Market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of Life Science Reagent Market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Scope of the Report:The all-encompassing research weighs up on various aspects including but not limited to important industry definition, product applications, and product types. The pro-active approach towards analysis of investment feasibility, significant return on investment, supply chain management, import and export status, consumption volume and end-use offers more value to the overall statistics on the Life Science Reagent Market. All factors that help business owners identify the next leg for growth are presented through self-explanatory resources such as charts, tables, and graphic images.

The key insights of the Corona impact on Life Science Reagent Market report::

The report provides key statistics on the market status of the Life Science Reagentmanufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. The report provides a basic overview of the industry including its definition, applications and manufacturing technology. The report presents the company profile, product specifications, capacity, production value, and 2014-2019 market shares for key vendors. The total market is further divided by company, by country, and by application/type for the competitive landscape analysis. The report estimates 2020-2026 market development trends of Life Science Reagent industry. Analysis of upstream raw materials, downstream demand, and current market dynamics is also carried out. The report makes some important proposals for a new project of Life Science Reagent industry before evaluating its feasibility.

Why Report Hive Research:Report Hive Research delivers strategic market research reports, statistical surveys, industry analysis and forecast data on products and services, markets and companies. Our clientele ranges mix of global business leaders, government organizations, SMEs, individuals and Start-ups, top management consulting firms, universities, etc. Our library of 700,000 + reports targets high growth emerging markets in the USA, Europe Middle East, Africa, Asia Pacific covering industries like IT, Telecom, Semiconductor, Chemical, Healthcare, Pharmaceutical, Energy and Power, Manufacturing, Automotive and Transportation, Food and Beverages, etc. This large collection of insightful reports assists clients to stay ahead of time and competition. We help in business decision-making on aspects such as market entry strategies, market sizing, market share analysis, sales and revenue, technology trends, competitive analysis, product portfolio, and application analysis, etc.

Touch With Us:

Report Hive Research

500, North Michigan Avenue,

Suite 6014,

Chicago, IL 60611,

United States

Website: https://www.reporthive.com

Email: [emailprotected]

Phone: +1 312-604-7084

Here is the original post:
Covid-19 impact on Life Science Reagent Market Analysis and Forecast 2020|Abcam,Emd Millipore,Biolog,Cell Sciences - Cole of Duty

State of the University Address – USC News

April 29, 2020

Hello and welcome Trojans.

Its such a privilege to speak with you today, about the state of our university, the times were in, and about our future a bright and promising one.

Thank you for attending this event; I hope you and your families are well.

Students are joining us for the first time; to them I say, welcome and Ill address you directly at the end of my speech.

I never expected to make history by Zooming this event and I would much prefer seeing and chatting with you before and after the talk. But Im confident those days too will return.

First though, I want to talk about the obvious. COVID-19 has hit us hard.

I know people are hurting and worried. Many are out of work. Thousands are in hospitals. Too many are dying, and it is heartbreaking.

Our people at USC are hurting too.

Your schedules and plans have been disrupted. Cherished events, like performances, competitions, thesis defenses, and commencement, have been postponed or changed. An entire athletic season has been erased. Youre missing friends, colleagues, and family you havent seen for weeks.

Some of you are working or studying from homes that werent prepared for this crisis, perhaps surrounded by people who need your attention or help.

Others are coming in to work, to help people still on campus, in spite of their own fears of the disease.

And I know, were all missing the joy and energy of being with our fellow students, colleagues, and friends.

It can feel very dark right now, but I see Trojans stepping up in this crisis every single day, under very difficult circumstances.

Im in awe of all of you.

Your strength is a beacon of hope.

Here are a few snapshots of that hope out of hundreds, I could cite

Ill start with our healthcare workers, in our hospitals, pharmacies, and clinics you heroically transformed yourselves overnight, to meet the pressing needs of patients throughout our region, prepare us for a surge, and advise the university about how to protect safety.

Faculty and staff, you swung into action, re-organizing completely the way you taught, mentored students, and went about your work.

Within five days, more than 6,000 courses were being reimagined and delivered remotely.

Our student life and housing staff helped 1,600 students who couldnt go home, to stay safely in their dorms. We began the Care-for-the Caregiver program, and are providing beds for USC and LA County health care workers. And our emergency staff began taking care of everyone.

The common denominator in all these examples, is a spirit of service and selflessness that animates so much of what we do.

For 140 years, USC has been part of the fabric of our region, and our city. And from the start of the crisis, Trojans have joined hands with community-based organizations, to support our most vulnerable neighbors.

USCs tireless volunteers delivered tens of thousands of meals to our neighbors, including those without shelter. Theyve made all sorts of PPE, provided two meals a day to our 500 Head Start kids and their families, organized a blood drive, and are helping nearly 3,000 small businesses to survive.

We see that same spirit of service in the remarkable work of our researchers, who are moving with lightning speed, to advance clinical trials, drug and vaccine development, pre-clinical therapeutic studies, and expand COVID-19 testing.

Theyre also helping people directly, providing telemedicine mental health counselling, and assisting public schools to adapt to COVID-19, and so much more.

Chances are, if youve heard about it, someone at USC is working on it and this is thanks in large part to COVID-19 innovation funds, created by the Provost, and added to, by generous parents, friends, and alumni from around the world.

Over my entire professional career, Ive never seen researchers and innovators come together, so quickly and with such purpose. I truly believe that in the end, science and human ingenuity, and care, will beat this.

COVID-19 may have knocked us hard but its also revealing sides of ourselves we may not have seen before.

As a biologist, Im reminded of the history of the microscope. Just over 400 years ago, Galileo, the extraordinary innovator he was, saw the power of magnifying lenses being made by Dutch master crafters and he used the lenses to complete the first microscope.

All of a sudden, the vast world of tiny organisms never seen before, became open to us, and just like that, human thinking was altered forever.

A year later, Galileo also perfected the telescope, expanding humanitys view into the universe, again changing forever what could be imagined.

One of the things I love most about teaching, is seeing my students reach that moment of clarity, when their understanding becomes crystal clear, and their horizons broaden.

I am seeing this in all of you, right now.

We are experiencing our own Galileo moment.

Were seeing problems as opportunities, exercising muscles we didnt know we had, tapping into wells of expertise and knowledge and compassion we didnt know were so deep.

Our entire workforce has turned on a dime, finding new ways to work together and solve problems, and helping people faster and more flexibly than ever before.

I believe now that weve seen and put these capabilities to use, in service of something bigger than ourselves, we wont, nor could we, go back.

This is what it feels like to collaborate at warp speed something Ive talked about before.

We see this happening so fully at USC because our community has been changing for some time now and, in important ways.

Weve been transforming our culture, our structure, and our governance, to enable us to become the university of the future and these changes are benefiting us now, as we adapt to meet the COVID-19 crisis.

So, let me turn to some of our key achievements that are driving a bold new vision for USC, for the coming decade. A full compilation of these accomplishments will be available on the USC website.

Ill start with our students, drawing on 48,000 individual stories, of achievement and cultural diversity.

USC has one of the most diverse student populations, and largest financial aid programs almost $650 million last year alone of the leading research universities in America.

And our incoming class, drawn from almost 60,000 talented applicants, is shaping up to be as accomplished and diverse as ever.

In fact, both Viterbi and Marshall are leading the nation among top-ranked schools, by welcoming classes at roughly gender parity.

Our students continue to say, they are coming to USC because it is the best place for them, to explore and pursue their passions, improve communities, and become game-changers.

Here they have the chance to work with some of the greatest minds of our times, and to get involved in so much.

This year, our students won numerous prestigious awards, with their talents on display in so many amazing ways.

They perform on Broadway, conduct ground-breaking research, write music, invent things, win competitions, and launch rockets. They volunteer their services and run businesses, and evaluate capital markets. They provide free legal clinics and medical and dental care. And they help feed, design, and house those without homes.

As graduates, theyll have an even bigger impact on their communities and in their fields, as our alumni always have.

USC is distinguished by its extraordinary breadth and strength. We see it, in our 23 academic units, in nearly $900 million in competitive research, and in our 28,000 graduate and professional students, and roughly 8,000 faculty.

The number of leading, top 10, and top 20 rankings received, by USC, our schools, and our departments, grew again this year.

Keck was ranked for the first time, as one of Americas top 20 hospitals. Childrens Hospital Los Angeles (CHLA) ranked number one in California, number one in the western United States, and number five in the country is the only leading childrens hospital that is a safety net hospital with more than 70 percent of its patients on Medicaid.

Reuters designated USC the eighth most innovative university in the world, and our graduates are often named Forbes 30 under 30 game-changers, in fields from arts to tech.

Our faculty continued to receive prestigious national honors including eight USC additions to the national academies of engineering, sciences, and inventors. Wow.

Theyre writing books and papers, changing the course of science, humanities, and policy. Theyre performing on stages worldwide, launching new companies, and pushing the frontiers of stem cell research. Theyre pushing to cure Alzheimers, cancer, and helping people to see again. Theyre leading the way in emerging fields, like Immuno bio-engineering, and working to end the educational, social, health, and economic disparities that plague our world.

And of course, all our achievements happen in partnership with our nearly 28,000 wonderful, determined, and dedicated staff many of whom are also our alumni. Im proud of the fact that we are the largest private employer in Los Angeles.

Our staff run our services from transportation to hospitality. Theyre part of our research and our teaching teams, they take care of our finances and our campuses; they keep us safe and our IT secure, they coach and care for our athletes.

They also care for our health and well-being, manage our operations, and organize our events. And they help us communicate, work with our stakeholders, and raise much needed financial support.

Our staff and faculty are incredibly generous as well, and I want to call this out. This year, we celebrated 25 years, during which thousands of our employees, donated 1 percent of their own salaries to support our Good Neighbors Program, to the tune of more than $26 million.

We also welcomed Chief Alma Burke, the first Latina and first female to serve as an Assistant Chief in USCs vitally important Department of Public Safety.

Finally, no State of the University speech would be complete without acknowledging the strength that comes from the Trojan family. Our alumni, parents, friends, and others are on the frontlines with us all the time, and they give generously to support our university.

USC simply wouldnt be who we are, without our alumni and their love of this very special place. They serve with great distinction, on our councils, in our Centers, and on our Board of Trustees.

Looking ahead, we know COVID-19 will continue to challenge us for some time. But I promise you, it will not deter us from reaching our goals.

Instead, we must take everything were learning in the fight against the pandemic like our newfound strength in collaboration, our willingness to change, our fresh perspective about where we are going and use it, to accelerate our transformation.

Specifically, we need to apply this knowledge and experience to deepen culture change, reinforce high ethical standards, and restructure our governance for a new, multidisciplinary, collaborative age.

Last September, I laid out four strategic goals for the university, and were making good progress here.

The first goal is to open our doors wider for students from all backgrounds. We want to make sure they truly flourish at USC, and become the leaders who build and succeed in the new economy.

Were making good on the historic pledge we made in the fall, to provide significantly more financial aid to low income students.

Were also on the way to doubling the mental health professionals at the student health center, expanding programs for First Gen, transfer, and undocumented students, and designing new spaces for student cultural groups, that do not currently have homes.

Our second goal is to take on sustainability, like never before, and build expertise that can reach around the world.

You may have heard about nature, returning to our locked-down cities along with clean air. Here in LA, once again, you could stand in one spot, and marvel at the crisply defined mountains to the east, and the sparkling Pacific Ocean to the west.

It reminds us what is possible, but it also shows us how much more we must do in the area of sustainability, to foster the kind of environment that will nurture us, and bring us joy.

Im proud of how far USC has come this year my zero-waste inauguration diverted an estimated 4,500 pounds of waste, from local landfills. Over 90 percent of waste is diverted at the Coliseum now, and I look forward to setting similar bold goals for the university overall.

Were on track to engage 75 percent of our departments in responsible purchasing, so that we can phase-out single use, non-essential plastics.

Were aggressively, pursuing a timeline for carbon neutrality, installing solar panels, subsidizing public transit, and supporting sustainability innovation funds.

And in just a few months the Presidential Working Group on Sustainability united around a number of recommendations to create the governance and educational programs, that will best help USC become a leader in sustainability.

Our third goal is to deepen our public partnerships, and become the leading university in reimaging the urban future. Here too, we are well on our way.

The COVID-19 crisis accelerated our efforts, to build and strengthen partnerships with city, county, state, and federal leaders.

It also put in stark relief, persistent inequalities in our society, that are having deadly effects, particularly in underserved communities of color.

For USC to be a leader in the urban future, we cant limit ourselves to being part of the recovery and building out of new economies; we also must be partners in the development of solutions to eliminate these enormous and destructive inequities.

For example, education and health systems need to accelerate efforts, to narrow disparities in the communities they serve, with solutions that can make a lasting difference.

As just one example, Im proud of the multidisciplinary efforts underway at Keck Medicine and the School of Medicine, to increase diversity in clinical trials.

They are energetically recruiting participants from areas of Los Angeles with large Latino populations, so they can be better represented in cardiac surgery clinical trials. This could go a long way in improving cardiac care for a large population.

And the fourth goal is to leverage the formidable talent of our faculty and schools, by pursuing bold ideas in areas where USC has a distinct advantage.

Our people are already hard-at-work considering moonshots, in big data and computational analytics, in building out the blue and green economies, in revolutionizing K-12 education, and in fast-tracking COVID-related research, that shows the greatest promise.

And there may be no other university better positioned than ours, to accelerate efforts to reimagine online education, and students educational experiences.

We have the experts right here: the best cinema school, the best gaming program, the most original technology for virtual reality, the best communications school, and extraordinary innovators in Viterbi, Iovine and Young, Rossier, Dornsife, Roski, and so on.

We sit at the epicenter of the imagination economy, and have extraordinary storytellers and technology leaders, who can bring education to life.

A great example of this is Dimensions in Testimony at the USC Shoah Foundation, a 3D educational experience, that is among the best in the world.

If we come together, and use the talent and tools we have, here and in Los Angeles, we can create a student experience unique to USC, that is second to none.

Underpinning these four goals, is our commitment to maintaining the highest ethical standards, in everything we do as a university.

Past scandals tarnished our reputation, and caused so much pain, across the Trojan community.

I spent a great deal of time this year listening, to students, faculty, alumni, and friends of USC, who shared their thoughts, on how we could bring back the luster to our university. I probably interacted with more than 40,000 people, and it was a wonderful, reaffirming experience.

Weve taken important, decisive steps this year in compliance, accountability, and transparency and we will continue these efforts, to ensure we stay on the right track going forward.

As we talk about the future, youre probably wondering what a post-COVID USC will look like. The pandemic will eventually subside, and when it does, well be ready.

Weve already launched Project Restart and are deep into planning for everyones return.

Schools are running full speed this summer online, and adding exciting new opportunities, and were re-building our infrastructure, to support more innovation and flexibility, when we do return.

Our decisions, about when and how to return, will be informed by a team of our leading public health professionals, along with state guidance and teams of experienced folks on our campuses.

Originally posted here:
State of the University Address - USC News

Ramona resident seeks speedy FDA approval for COVID-19 stem cell treatment – The San Diego Union-Tribune

Ramona resident Bob Harman is applying his expertise in the veterinary and biotech fields toward developing a stem cell treatment for COVID-19.

As CEO of Personalized Stem Cells, Inc. in Poway, Dr. Harman is involved in the companys quest to have the Food & Drug Administration (FDA) fast-track its Investigational New Drug application for the treatment of COVID-19 patients with stem cells.

Personalized Stem Cells parent, VetStem Biopharma, has provided stem cells for treatment of more than 15,000 dogs and horses and for treatment of animals at the San Diego Zoo, Safari Park and at SeaWorld.

Personalized Stem Cells has provided stem cells for an FDA approved human clinical trial for treatment of knee arthritis. Future stem cell clinical trials are planned for back pain, Traumatic Brain Injury, and opioid addiction.

Harmans own work with stem cells dates back to the 2007 Witch Creek fire when two of his horses were caught in a burning horse trailer in Ramona. The horses suffered severe smoke inhalation, but Harman said after he treated them with stem cells there were no signs of lung damage.

Personalized Stem Cells is developing a stem cell treatment for COVID-19 patients.

(Richard Deomampo - The Right Light)

Fast-forward 13 years and Harman sees the same possibilities to repair damaged lungs in COVID-19 patients using stem cells. Harman said the FDA is currently reviewing the Investigational New Drug application for its stem cell therapy in COVID-19 patients.

At the encouragement of the White House Coronavirus Task Force, Personalized Stem Cells has applied to the FDAs Coronavirus Therapeutic Accelerator Program which could expedite clinical trials.

If the FDA approves the application, which Harman foresees as imminent, Personalized Stem Cells would initiate a clinical trial to test the effectiveness of stem cells in COVID-19 patients.

Harman anticipates the first 20 patients in the CoronaStem 1 trial could be treated late this week or early next week at Sharp Grossmont Hospital in La Mesa, pending approvals.

Personalized Stem Cells also plans to ask the FDA to allow compassionate use of the stem cell treatment, which Harman said would provide early and widespread access to the treatment without clinical trials.

Here at Poway, we can make doses to treat 10,000 patients each month if approved by the FDA, Harman said.

Personalized Stem Cells has filed for expedited FDA approval to treat COVID-19 patients.

(Richard Deomampo - The Right Light)

The CEO said other companies developing similar but different stem cell treatments in Australia, China and Israel have demonstrated striking results in COVID-19 patients in intensive care units. He said stem cells have been injected intravenously to allow the stem cells to enter the lungs where they help reduce inflammation and damage to the patients lungs. Harman cites a 50 percent to 90 percent reduction rate in patient deaths related to COVID-19 in these countries.

Ventilators are not the solution to treating patients, he said, because as many as 90 percent of COVID-19 patients die while connected to ventilators.

Everybody talks about the need to manufacture ventilators, he said. Thats a last-ditch effort. Once youre on a mechanical ventilator its bad news. Ive never seen anything as dramatic as the possibilities for using stem cells to treat COVID-19.

The treatment Personalized Stem Cells is developing could also potentially be used to treat influenza patients and those affected by other virus outbreaks in the future, he said.

Personalized Stem Cells method of growing stem cells starts by collecting cells from adult fat tissue. Harman explained that donors supply the cells through liposuction procedures. The cells are tested to ensure they are disease-free and are then grown in sterile clean rooms. He said the cells will multiply, creating a large volume of stem cells that are packaged and frozen so they can be stored up to 20 years.

If and when the CoronaStem 1 trial is completed, which Harman estimates at the earliest could be within 90 days, the company would apply to the FDA to conduct a larger CoronaStem 2 trial possibly involving other hospitals in California. Depending on how well the stem cells perform in the first phase of study, the FDA could also approve widespread distribution of Personalized Stem Cells treatment.

Harman predicts that there may be a downward trend in COVID-19s spread by early summer, but he expects it will continue to linger.

The prediction that by summer this will be on a downturn is very real as long as we keep up appropriate safety measures, he said. I think we will see that by early summer it will slow down, but it wont be gone. Its not just going to disappear. It doesnt go away easily.

Personalized Stem Cells and VetStem Biopharma, which have 31 employees combined, are actively pursuing grants and donations to prepare for ramped up production of stem cells. Calidi Biotherapeutics is collaborating with Personalized Stem Cells to provide needed cell lines and supplies to speed stem cell manufacturing. But money is also needed to pay the doctors, nurses, imaging technicians, laboratories and others involved in performing the medical procedures for the clinical trial. In addition to seeking government grants, Personalized Stem Cells is reaching out to philanthropic groups such as the Gates Foundation and is partnering with the nonprofit The San Diego Foundation to accept donations.

Everyone wants to help, and this is something very tangible that you can do, Harman said. We are raising additional capital to be able to provide stem cell therapy to a wider population and potentially to underserved groups.

More information is available online at https://personalizedstemcells.com/covid-19/.

Read the original here:
Ramona resident seeks speedy FDA approval for COVID-19 stem cell treatment - The San Diego Union-Tribune